Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
COVID-19 Booster Study Shows Efficacy: Daiichi Sankyo
Daiichi Sankyo said on May 26 that its investigational mRNA vaccine against COVID-19 (DS-5670) demonstrated efficacy in a domestic booster dose trial. The results of this first dose-finding part in the Japan PI/II/III clinical study showed that the booster effect…
To read the full story
Related Article
- Daiichi Sankyo Files First Home-Developed mRNA COVID Vaccine in Japan
January 16, 2023
- Daiichi Sankyo’s COVID Jab Hits Mark in Japan Booster Trial, Filing Set for January
November 16, 2022
- Daiichi Sankyo Begins PIII Primary Dose Study for mRNA COVID Jab
September 2, 2022
- Daiichi Sankyo Initiates COVID-19 Booster Study in Japan
February 1, 2022
- Daiichi Sankyo Begins PII for COVID-19 mRNA Vaccine, Eyes 2022 Rollout
November 18, 2021
- Daiichi Sankyo Eyes Booster Dose Trial Launch in January
October 22, 2021
- Daiichi Sankyo Begins Japan PI/II for mRNA COVID-19 Vaccine
March 23, 2021
BUSINESS
- RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
- Obesity Market Projected at 46.6 Billion Yen by 2040 as GLP-1s Fuel Growth: Fuji Keizai
December 15, 2025
- Roche Diagnostics Taps Ex-Medtronic Japan VP Maeda as New CEO
December 15, 2025
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
- Scrap “Spillover,” “Special” Rules If G1 Rule Is Applied Early: Chugai CEO
December 15, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…